Modest 10% reductions in circulating total lymphocytes, CD4+ and CD8+ T cells, and B cells were observed in patients with MS after 1 year of daclizumab beta 150 mg treatment, and regulatory T cell levels were reduced by approximately 50% after 8 weeks [92–94]. This evidence concerns the gene CD4 and myeloid sarcoma.